Mechanism of thioamide drug action against tuberculosis and leprosy

Journal of Experimental Medicine

Volumn 204, Issue 1, 2007, Pages 73-78

  Wang, Feng ^a   Langley, Robert ^a   Gulten, Gulcin ^a   Dover, Lynn G ^c   Besra, Gurdyal S ^c   Jacobs Jr , William R ^b   Sacchettini, James C ^a,c  

^a TEXAS A AND M UNIVERSITY   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ETHIONAMIDE; NICOTINAMIDE ADENINE DINUCLEOTIDE; PROTIONAMIDE; THIOACETAMIDE;

ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; LEPROSY; MYCOBACTERIUM AVIUM; MYCOBACTERIUM LEPRAE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; TUBERCULOSIS;

ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; CRYSTALLOGRAPHY, X-RAY; DRUG DESIGN; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ETHIONAMIDE; HUMANS; LEPROSTATIC AGENTS; LEPROSY; MODELS, MOLECULAR; MYCOBACTERIUM AVIUM COMPLEX; MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION; MYCOBACTERIUM LEPRAE; MYCOBACTERIUM TUBERCULOSIS; NAD; OXIDOREDUCTASES; PROTHIONAMIDE; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 33846446699     PISSN: 00221007     EISSN: 00221007     Source Type: Journal    
DOI: 10.1084/jem.20062100     Document Type: Article

References (30)

1. Fajardo, T.T., R.S. Guinto, R.V. Cellona, R.M. Abalos, E.C. Dela Cruz, and R.H. Gelber. 2006. A clinical trial of ethionamide and prothionamide for treatment of lepromatous leprosy. Am. J. Trop. Med. Hyg. 74:457-461.
2. Yajko, D.M., P.S. Nassos, and W.K. Hadley. 1987. Therapeutic implications of inhibition versus killing of Mycobacterium avium complex by antimicrobial agents. Antimicrob. Agents Chemother. 31:117-120.
3. Centers for Disease Control and Prevention. 2006. Emergence of Mycobacterium tuberculosis with extensive resistance to second-line drugs-worldwide, 2000-2004. MMWR Morb. Mortal. Wkly. Rep. 55:301-305.
4. Crofton, J., P. Chaulet, D. Maher, J. Grosset, W. Harris, H. Norman, M. Iseman, and B. Watt. 1997. Guidelines for the Management of Multidrug-Resistant Tuberculosis. World Health Organization: Geneva, Switzerland.
5. Katoch, K., M. Natarajan, A.S. Bhatia, and V.S. Yadav. 1992. Treatment of paucibacillary leprosy with a regimen containing rifampicin, dapsone and prothionamide. Indian J. Lepr. 64:303-312.
6. Banerjee, A., E. Dubnau, A. Quemard, V. Balasubramanian, K.S. Um, T. Wilson, D. Collins, G. de Lisle, and W.R. Jacobs Jr. 1994. inhA, a gene encoding a target for isoniazid and ethionamide in Mycobacterium tuberculosis. Science. 263:227-230.
7. Rozwarski, D.A., G.A. Grant, D.H. Barton, W.R. Jacobs Jr., and J.C. Sacchettini. 1998. Modification of the NADH of the isoniazid target (InhA) from Mycobacterium tuberculosis. Science. 279:98-102.
8. Vilcheze, C., F. Wang, M. Arai, M.H. Hazbon, R. Colangeli, L. Kremer, T.R. Weisbrod, D. Alland, J.C. Sacchettini, and W.R. Jacobs Jr. 2006. Transfer of a point mutation in Mycobacterium tuberculosis inhA resolves the target of isoniazid. Nat. Med. 12:1027-1029.
9. Takayama, K., L. Wang, and H.L. David. 1972. Effect of isoniazid on the in vivo mycolic acid synthesis, cell growth, and viability of Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2:29-35.
10. Winder, F.G., P.B. Collins, and D. Whelan. 1971. Effects of ethionamide and isoxyl on mycolic acid synthesis in Mycobacterium tuberculosis BCG. J. Gen. Microbiol. 66:379-380.
11. Wilson, T.M., G.W. de Lisle, and D.M. Collins. 1995. Effect of inhA and katG on isoniazid resistance and virulence of Mycobacterium bovis. Mol. Microbiol. 15:1009-1015.
12. Larsen, M.H., C. Vilcheze, L. Kremer, G.S. Besra, L. Parsons, M. Salfinger, L. Heifets, M.H. Hazbon, D. Alland, J.C. Sacchettini, and W.R. Jacobs Jr. 2002. Overexpression of inhA, but not kasA, confers resistance to isoniazid and ethionamide in Mycobacterium smegmatis, M. bovis BCG and M. tuberculosis. Mol. Microbiol. 46:453-466.
13. Morlock, G.P., B. Metchock, D. Sikes, J.T. Crawford, and R.C. Cooksey. 2003. ethA, inhA, and katG loci of ethionamide-resistant clinical Mycobacterium tuberculosis isolates. Antimicrob. Agents Chemother. 47:3799-3805.
14. Dessen, A., A. Quemard, J.S. Blanchard, W.R. Jacobs Jr., and J.C. Sacchettini. 1995. Crystal structure and function of the isoniazid target of Mycobacterium tuberculosis. Science. 267:1638-1641.
15. Johnsson, K., and P.G. Schultz. 1994. Mechanistic Studies of the Oxidation of Isoniazid by the Catalase Peroxidase from Mycobacterium tuberculosis. J. Am. Chem. Soc. 116:7425-7426.
16. Lei, B., C.J. Wei, and S.C. Tu. 2000. Action mechanism of antitubercular isoniazid. Activation by Mycobacterium tuberculosis KatG, isolation, and characterization of inha inhibitor. J. Biol. Chem. 275:2520-2526.
17. Johnsson, K., D.S. King, and P.G. Schultz. 1995. Studies on the Mechanism of Action of Isoniazid and Ethionamide in the Chemotherapy of Tuberculosis. J. Am. Chem. Soc. 117:5009-5010.
18. Zhang, Y., B. Heym, B. Allen, D. Young, and S. Cole. 1992. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature. 358:591-593.
19. Fattorini, L., E. Iona, M.L. Ricci, O.F. Thoresen, G. Orru, M.R. Oggioni, E. Tortoli, C. Piersimoni, P. Chiaradonna, M. Tronci, et al. 1999. Activity of 16 antimicrobial agents against drug-resistant strains of Mycobacterium tuberculosis. Microb. Drug Resist. 5:265-270.
20. DeBarber, A.E., K. Mdluli, M. Bosman, L.G. Bekker, and C.E. Barry III. 2000. Ethionamide activation and sensitivity in multidrug-resistant Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. USA. 97:9677-9682.
21. Baulard, A.R., J.C. Betts, J. Engohang-Ndong, S. Quan, R.A. McAdam, P.J. Brennan, C. Locht, and G.S. Besra. 2000. Activation of the pro-drug ethionamide is regulated in mycobacteria. J. Biol. Chem. 275:28326-28331.
22. Fraaije, M.W., N.M. Kamerbeek, A.J. Heidekamp, R. Fortin, and D.B. Janssen. 2004. The prodrug activator EtaA from Mycobacterium tuberculosis is a Baeyer-Villiger monooxygenase. J. Biol. Chem. 279:3354-3360.
23. Vannelli, T.A., A. Dykman, and P.R. Ortiz de Montellano. 2002. The antituberculosis drug ethionamide is activated by a flavoprotein monooxygenase. J. Biol. Chem. 277:12824-12829.
24. Quemard, A., G. Laneelle, and C. Lacave. 1992. Mycolic acid synthesis: a target for ethionamide in mycobacteria? Antimicrob. Agents Chemother. 36:1316-1321.
25. Tokuyama, H., T. Yamashita, M.T. Reding, Y. Kaburagi, and T. Fukuyama. 1999. Radical Cyclization of 2-Alkenylthioanilides: A Novel Synthesis of 2,3-Disubstituted Indoles. J. Am. Chem. Soc. 121:3791-3792.
26. Vilcheze, C., T.R. Weisbrod, B. Chen, L. Kremer, M.H. Hazbon, F. Wang, D. Alland, J.C. Sacchettini, and W.R. Jacobs Jr. 2005. Altered NADH/NAD+ ratio mediates coresistance to isoniazid and ethionamide in mycobacteria. Antimicrob. Agents Chemother. 49:708-720.
27. McPherson, A. 1982. Preparation and Analysis of Protein Crystals. John Wiley & Sons Inc., New York. 371 pp.
28. Otwinowski, Z., and W. Minor. 1997. Processing of x-ray diffraction data collected in oscillation mode. In Methods in Enzymology. C.W. Carter and R.M. Sweet, editors. Academic Press, New York. 307-326.
29. Brunger, A.T., P.D. Adams, G.M. Clore, W.L. DeLano, P. Gros, R.W. Grosse-Kunstleve, J.S. Jiang, J. Kuszewski, M. Nilges, N.S. Pannu, et al. 1998. Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr. D Biol. Crystallogr. 54:905-921.
30. McRee, D.E. 1999. XtalView/Xfit-A versatile program for manipulating atomic coordinates and electron density. J. Struct. Biol. 125:156-165.